Home > Publications database > Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. > print

001     166641
005     20240229133526.0
024 7 _ |a 10.1016/j.cellimm.2020.104274
|2 doi
024 7 _ |a pmid:33383383
|2 pmid
024 7 _ |a 0008-8749
|2 ISSN
024 7 _ |a 1090-2163
|2 ISSN
024 7 _ |a altmetric:96831647
|2 altmetric
037 _ _ |a DKFZ-2021-00008
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Gebhardt, Christoffer
|0 P:(DE-He78)d239d6a28875058b40c13266babadb58
|b 0
|e First author
245 _ _ |a Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1609840039_26094
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume 360, February 2021, 104274#EA:A370#LA:A370#
520 _ _ |a The low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8+ T cells and their activity indicated by the upregulation of CD25 and TCR ζ-chain expression. Our study suggests that low-dose paclitaxel treatment could improve clinical outcome of some advanced melanoma patients by enhancing anti-tumor immunity and might be proposed for combined melanoma immunotherapy.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|x 0
|f POF IV
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Immune checkpoint blockade
|2 Other
650 _ 7 |a Immunotherapy
|2 Other
650 _ 7 |a Melanoma
|2 Other
650 _ 7 |a Myeloid suppressor cells
|2 Other
650 _ 7 |a Paclitaxel
|2 Other
700 1 _ |a Simon, Sonja C S
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Weber, Rebekka
|0 P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df
|b 2
|u dkfz
700 1 _ |a Gries, Mirko
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Mun, Dong Hun
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Reinhard, Raphael
|b 5
700 1 _ |a Holland-Letz, Tim
|0 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
|b 6
|u dkfz
700 1 _ |a Umansky, Viktor
|0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
|b 7
|u dkfz
700 1 _ |a Utikal, Jochen
|0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.cellimm.2020.104274
|g Vol. 360, p. 104274 -
|0 PERI:(DE-600)1462601-9
|p 104274
|t Cellular immunology
|v 360
|y 2021
|x 0008-8749
909 C O |o oai:inrepo02.dkfz.de:166641
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)d239d6a28875058b40c13266babadb58
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Signalling pathways, cell and tumor biology
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-09-09
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-09
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL IMMUNOL : 2018
|d 2020-09-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-09-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-09-09
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-09-09
920 1 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A370-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21